Duygu Ürek1, Özgür Uğurluoğlu2. 1. Department of Health Care Management, Faculty of Economics and Administrative Sciences, Hacettepe University, Beytepe Campus, 06800, Ankara, Turkey. duyguurek@hacettepe.edu.tr. 2. Department of Health Care Management, Faculty of Economics and Administrative Sciences, Hacettepe University, Beytepe Campus, 06800, Ankara, Turkey.
Abstract
PURPOSE: This study aims to determine the financial toxicity (FT) level in cancer patients, identify the risk factors associated with this level, and reveal the effect of this level on patient outcomes (health-related quality of life (HRQoL) and treatment non-adherence). METHODS: The data of 316 cancer patients, who were receiving inpatient treatment in an oncology hospital affiliated to a public university in Ankara, Turkey, were ≥ 18 years old, and were receiving chemotherapy for at least 3 months, were evaluated. The data were collected through a face-to-face interview. FT was measured with the COmprehensive Score for financial Toxicity (COST) Measure (v2), HRQoL was measured with the Functional Assessment of Cancer Therapy-General (FACT-G) Scale (v4), and treatment adherence was measured using a questionnaire created by conducting a literature review. RESULTS: Patients were found to experience FT above the moderate level (mean ± SD, 21.85 ± 12.02; median value, 24.0). Younger age, being married, low education level, low monthly household income, and receiving social/economic support for treatment were revealed to be the determinants of high FT. Moreover, as the FT score decreased (as the FT level felt increased), the HRQoL was observed to decrease, and treatment non-adherence increased. CONCLUSION: The results indicate that FT problem is also valid for cancer patients in Turkey despite the system of general health insurance. The FT was found to result from socio-economic characteristics rather than the disease and treatment-related characteristics. The significant associations revealed between FT and patient outcomes emphasize the importance of reducing the FT in cancer patients.
PURPOSE: This study aims to determine the financial toxicity (FT) level in cancer patients, identify the risk factors associated with this level, and reveal the effect of this level on patient outcomes (health-related quality of life (HRQoL) and treatment non-adherence). METHODS: The data of 316 cancer patients, who were receiving inpatient treatment in an oncology hospital affiliated to a public university in Ankara, Turkey, were ≥ 18 years old, and were receiving chemotherapy for at least 3 months, were evaluated. The data were collected through a face-to-face interview. FT was measured with the COmprehensive Score for financial Toxicity (COST) Measure (v2), HRQoL was measured with the Functional Assessment of Cancer Therapy-General (FACT-G) Scale (v4), and treatment adherence was measured using a questionnaire created by conducting a literature review. RESULTS: Patients were found to experience FT above the moderate level (mean ± SD, 21.85 ± 12.02; median value, 24.0). Younger age, being married, low education level, low monthly household income, and receiving social/economic support for treatment were revealed to be the determinants of high FT. Moreover, as the FT score decreased (as the FT level felt increased), the HRQoL was observed to decrease, and treatment non-adherence increased. CONCLUSION: The results indicate that FT problem is also valid for cancer patients in Turkey despite the system of general health insurance. The FT was found to result from socio-economic characteristics rather than the disease and treatment-related characteristics. The significant associations revealed between FT and patient outcomes emphasize the importance of reducing the FT in cancer patients.
Authors: Jonas A de Souza; Bonnie J Yap; Fay J Hlubocky; Kristen Wroblewski; Mark J Ratain; David Cella; Christopher K Daugherty Journal: Cancer Date: 2014-06-20 Impact factor: 6.860
Authors: Whitney H Beeler; Emily L Bellile; Keith A Casper; Elizabeth Jaworski; Nicholas J Burger; Kelly M Malloy; Matthew E Spector; Andrew G Shuman; Andrew Rosko; Chaz L Stucken; Steven B Chinn; Aleksandar F Dragovic; Christina H Chapman; Dawn Owen; Shruti Jolly; Carol R Bradford; Mark E P Prince; Francis P Worden; Reshma Jagsi; Michelle L Mierzwa; Paul L Swiecicki Journal: Oral Oncol Date: 2019-12-23 Impact factor: 5.337
Authors: Chuo Yew Ting; Guan Chou Teh; Kong Leong Yu; Haridah Alias; Hui Meng Tan; Li Ping Wong Journal: Support Care Cancer Date: 2019-07-10 Impact factor: 3.603
Authors: Sara Bouberhan; Meghan Shea; Alice Kennedy; Adrienne Erlinger; Hannah Stack-Dunnbier; Mary K Buss; Laureen Moss; Kathleen Nolan; Christopher Awtrey; John L Dalrymple; Leslie Garrett; Fong W Liu; Michele R Hacker; Katharine M Esselen Journal: Gynecol Oncol Date: 2019-04-30 Impact factor: 5.482
Authors: Christopher J Longo; Margaret I Fitch; Laura Banfield; Paul Hanly; K Robin Yabroff; Linda Sharp Journal: Support Care Cancer Date: 2020-07-11 Impact factor: 3.603
Authors: Jonas A de Souza; Bonnie J Yap; Kristen Wroblewski; Victoria Blinder; Fabiana S Araújo; Fay J Hlubocky; Lauren H Nicholas; Jeremy M O'Connor; Bruce Brockstein; Mark J Ratain; Christopher K Daugherty; David Cella Journal: Cancer Date: 2016-10-07 Impact factor: 6.860